Founded in 2016 as Droplet Genomics, Atrandi Biosciences is dedicated to high-throughput analysis of single cells through its innovative technologies.

Atrandi Biosciences, a Vilnius-based biotech company, has successfully raised $25 million in Series A funding to enhance its single-cell research capabilities in the United States.

The funding round was led by Lux Capital, with contributions from Vsquared Ventures, Practica Capital, Metaplanet, and GRIDS Capital.

Atrandi specializes in single-cell sample preparation technology, utilizing semipermeable capsules for precise molecular analysis while maintaining single-cell resolution.

The company offers a range of platforms, including Flux, Styx, and Onyx, which are utilized in various applications such as microbial genomics and fluorescence-based cell detection.

This investment will allow Atrandi to further develop its microfluidic platforms, launch new products, and facilitate its entry into the competitive US market.

CEO Juozas Nainys has emphasized Lithuania's burgeoning biotech scene, likening it to the early days of Silicon Valley.

With a workforce of over 65 employees, Atrandi aims to bolster its operations and establish a stronger presence in the US biotech landscape.

Previously, in 2023, Atrandi raised $4.8 million and is now planning to open an office in Boston as part of its strategic growth initiatives.